This inventor holds 1 USPTO granted patent. Top assignees: Cellular Biomedicine Group (Shanghai) Ltd., Cellular Biomedicine Group (Wuxi) Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 4 
1 out of 4 Years Active: 2026
Title: Yanfeng Li: Innovator in Chimeric Antigen Receptor Technology
Introduction
Yanfeng Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biomedical engineering, particularly in the development of chimeric antigen receptors (CARs). His work focuses on enhancing the efficacy of T cell therapies for cancer treatment.
Latest Patents
Yanfeng Li holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in targeted cancer therapies, specifically for conditions involving the CD20 antigen.
Career Highlights
Throughout his career, Yanfeng Li has worked with notable organizations, including Cellular Biomedicine Group (Shanghai) Ltd. and Cellular Biomedicine Group (Wuxi) Ltd. His experience in these companies has allowed him to contribute to cutting-edge research and development in the field of cellular therapies.
Collaborations
Yanfeng Li has collaborated with esteemed colleagues such as Yihong Yao and Jiaqi Huang. These partnerships have fostered innovation and have been instrumental in advancing their shared goals in biomedical research.
Conclusion
Yanfeng Li's contributions to the field of chimeric antigen receptor technology highlight his role as a key innovator in cancer treatment. His patent and collaborative efforts reflect his commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile